menu
    • menu
    [{"orgOrder":0,"company":"Anergis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Amino Acid","year":"2012","type":"Inapplicable","leadProduct":"Histamine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Anergis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anergis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Anergis \/ Undisclosed"},{"orgOrder":0,"company":"Groupe Francophone des Myelodysplasies","sponsor":"EpiCept","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Amino Acid","year":"2011","type":"Inapplicable","leadProduct":"Histamine Dihydrochloride","moa":"Immune","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Groupe Francophone des Myelodysplasies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe Francophone des Myelodysplasies \/ EpiCept","highestDevelopmentStatusID":"7","companyTruncated":"Groupe Francophone des Myelodysplasies \/ EpiCept"},{"orgOrder":0,"company":"Vastra Gotaland Region","sponsor":"Karolinska University Hospital | Nordic MDS Group | Sahlgrenska University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Amino Acid","year":"2017","type":"Inapplicable","leadProduct":"Histamine Dihydrochloride","moa":"Immune","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vastra Gotaland Region","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vastra Gotaland Region \/ Karolinska University Hospital | Nordic MDS Group | Sahlgrenska University Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Vastra Gotaland Region \/ Karolinska University Hospital | Nordic MDS Group | Sahlgrenska University Hospital"},{"orgOrder":0,"company":"Noventia Pharma","sponsor":"Delbert Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Amino Acid","year":"2022","type":"Acquisition","leadProduct":"Histamine Dihydrochloride","moa":"||Immune","graph1":"Oncology","graph2":"Approved FDF","graph3":"Noventia Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Noventia Pharma \/ Delbert Lab","highestDevelopmentStatusID":"15","companyTruncated":"Noventia Pharma \/ Delbert Lab"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"EpiCept","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Amino Acid","year":"2011","type":"Inapplicable","leadProduct":"Histamine Dihydrochloride","moa":"Immune","graph1":"Oncology","graph2":"Phase IV","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytovia Therapeutics \/ EpiCept","highestDevelopmentStatusID":"11","companyTruncated":"Cytovia Therapeutics \/ EpiCept"}]

    Find Clinical Drug Pipeline Developments & Deals for Histamine Dihydrochloride

    Menu

    Histamine Dihydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Noventia Pharma

                            Italy arrow
                            CPhI India
                            Not Confirmed

                            Noventia Pharma

                            Italy arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Histamine Dihydrochloride,Interleukin 2

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Delbert Lab

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            DELBERT Laboratories Are Proud to Announce the Acquisition From Noventia Pharma Srl of the European Marketing ...

                            Details : Ceplene® demonstrated a clinical interest in maintenance treatment of acute myeloid leukemia (AML) in patients below 60 years of age in first "complete remission" (symptom-free period of disease after initial treatment) in a clinical study.

                            Product Name : Ceplene

                            Product Type : Amino Acid

                            Upfront Cash : Undisclosed

                            November 18, 2022

                            Lead Product(s) : Histamine Dihydrochloride,Interleukin 2

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Delbert Lab

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vastra Gotaland Region

                            Country arrow
                            CPhI India
                            Not Confirmed

                            Vastra Gotaland Region

                            Country arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Histamine Dihydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Karolinska University Hospital | Nordic MDS Group | Sahlgrenska University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)

                            Details : Histamine Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Leukemia, Myelomonocytic, Chronic.

                            Product Name : Undisclosed

                            Product Type : Amino Acid

                            Upfront Cash : Inapplicable

                            February 02, 2017

                            Lead Product(s) : Histamine Dihydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Karolinska University Hospital | Nordic MDS Group | Sahlgrenska University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Anergis

                            Country arrow
                            CPhI India
                            Not Confirmed

                            Anergis

                            Country arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Histamine Dihydrochloride

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Skin Prick Tests With AllerT in Subjects Allergic to Birch Pollen

                            Details : Histamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Rhinitis, Allergic.

                            Product Name : Undisclosed

                            Product Type : Amino Acid

                            Upfront Cash : Inapplicable

                            November 01, 2012

                            Lead Product(s) : Histamine Dihydrochloride

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cytovia Therapeutics

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Cytovia Therapeutics

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Histamine Dihydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase IV

                            Sponsor : EpiCept

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia

                            Details : Histamine Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Amino Acid

                            Upfront Cash : Inapplicable

                            May 05, 2011

                            Lead Product(s) : Histamine Dihydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase IV

                            Sponsor : EpiCept

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Groupe Francophone des Myelodysplasies

                            Country arrow
                            CPhI India
                            Not Confirmed

                            Groupe Francophone des Myelodysplasies

                            Country arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Histamine Dihydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : EpiCept

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes

                            Details : Histamine Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Myelodysplastic Syndromes.

                            Product Name : Undisclosed

                            Product Type : Amino Acid

                            Upfront Cash : Inapplicable

                            March 29, 2011

                            Lead Product(s) : Histamine Dihydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : EpiCept

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth